<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36845162</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseases.</ArticleTitle><Pagination><StartPage>1106537</StartPage><MedlinePgn>1106537</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1106537</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1106537</ELocationID><Abstract><AbstractText>Autoimmune diseases vary in the magnitude and diversity of autoantibody profiles, and these differences may be a consequence of different types of breaks in tolerance. Here, we compared the disparate autoimmune diseases autoimmune polyendocrinopathy-candidiasis-ecto-dermal dystrophy (APECED), systemic lupus erythematosus (SLE), and Sjogren's syndrome (SjS) to gain insight into the etiology of breaks in tolerance triggering autoimmunity. APECED was chosen as a prototypical monogenic disease with organ-specific pathology while SjS and SLE represent polygenic autoimmunity with focal or systemic disease. Using protein microarrays for autoantibody profiling, we found that APECED patients develop a focused but highly reactive set of shared mostly anti-cytokine antibodies, while SLE patients develop broad and less expanded autoantibody repertoires against mostly intracellular autoantigens. SjS patients had few autoantibody specificities with the highest shared reactivities observed against Ro-52 and La. RNA-seq B-cell receptor analysis revealed that APECED samples have fewer, but highly expanded, clonotypes compared with SLE samples containing a diverse, but less clonally expanded, B-cell receptor repertoire. Based on these data, we propose a model whereby the presence of autoreactive T-cells in APECED allows T-dependent B-cell responses against autoantigens, while SLE is driven by breaks in peripheral B-cell tolerance and extrafollicular B-cell activation. These results highlight differences in the autoimmunity observed in several monogenic and polygenic disorders and may be generalizable to other autoimmune diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Clarke, Du, Kumar, Okitsu, Schuette, An, Zhang, Tzvetkov, Jensen, Niewold, Ferre, Nardone, Lionakis, Vlach, DeMartino and Bender.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Satyendra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okitsu</LastName><ForeName>Shinji L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuette</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Protein Engineering and Antibody Technologies, Merck KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzvetkov</LastName><ForeName>Evgeni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niewold</LastName><ForeName>Timothy B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Immunology, Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferre</LastName><ForeName>Elise M N</ForeName><Initials>EMN</Initials><AffiliationInfo><Affiliation>Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardone</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lionakis</LastName><ForeName>Michail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlach</LastName><ForeName>Jaromir</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMartino</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bender</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>TIP Immunology, EMD Serono, Billerica, MA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016884" MajorTopicYN="Y">Polyendocrinopathies, Autoimmune</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell receptor (BCR)</Keyword><Keyword MajorTopicYN="N">Sjogren's syndrome</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">autoimmune disease (AD)</Keyword><Keyword MajorTopicYN="N">autoimmune polyendocrinopathy candidiasis ecotodermal dystrophy (APECED)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>TC, PD, SK, SO, MS, QA, JZ, ET, JV, JD, AB are/have been employees of EMD Serono, Billerica MA, USA or Merck KGaA, Darmstadt, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. The authors declare that this study received funding from EMD Serono Inc and Merck KGaA. The funders were involved in the study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>4</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36845162</ArticleId><ArticleId IdType="pmc">PMC9955420</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1106537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol Rev (2019) 287(1):103&#x2013;20. doi: 10.1111/imr.12714</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12714</ArticleId><ArticleId IdType="pmc">PMC6309421</ArticleId><ArticleId IdType="pubmed">30565240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. . Positional cloning of the APECED gene. Nat Genet (1997) 17(4):393&#x2013;8. doi: 10.1038/ng1297-393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1297-393</ArticleId><ArticleId IdType="pubmed">9398839</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnish-German AC. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet (1997) 17(4):399&#x2013;403. doi: 10.1038/ng1297-399</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1297-399</ArticleId><ArticleId IdType="pubmed">9398840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Orlova E, Sozaeva L, Levy R, James A, Schmitt MM, et al. . Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med (2021) 218(7). doi: 10.1084/jem.20210554</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210554</ArticleId><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (2020) 370(6515). doi: 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. . Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med (2010) 207(2):299&#x2013;308. doi: 10.1084/jem.20091669</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091669</ArticleId><ArticleId IdType="pmc">PMC2822605</ArticleId><ArticleId IdType="pubmed">20123959</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. . Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med (2010) 207(2):291&#x2013;7. doi: 10.1084/jem.20091983</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091983</ArticleId><ArticleId IdType="pmc">PMC2822614</ArticleId><ArticleId IdType="pubmed">20123958</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol (2017) 18(7):716&#x2013;24. doi: 10.1038/ni.3731</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3731</ArticleId><ArticleId IdType="pmc">PMC5791156</ArticleId><ArticleId IdType="pubmed">28632714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. . Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol (2015) 16(7):755&#x2013;65. doi: 10.1038/ni.3175</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3175</ArticleId><ArticleId IdType="pmc">PMC4512288</ArticleId><ArticleId IdType="pubmed">26006014</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (2021) 80(1):14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-ro and anti-la antibodies in primary sjogren's syndrome. Autoimmun Rev (2011) 10(3):123&#x2013;5. doi: 10.1016/j.autrev.2010.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2010.09.001</ArticleId><ArticleId IdType="pubmed">20833272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman D, Kisand K, Hertel C, Rothe M, Remm A, Pihlap M, et al. . Autoantibody repertoire in APECED patients targets two distinct subgroups of proteins. Front Immunol (2017) 8:976. doi: 10.3389/fimmu.2017.00976</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00976</ArticleId><ArticleId IdType="pmc">PMC5561390</ArticleId><ArticleId IdType="pubmed">28861084</ArticleId></ArticleIdList></Reference><Reference><Citation>Landegren N, Sharon D, Freyhult E, Hallgren A, Eriksson D, Edqvist PH, et al. . Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1. Sci Rep (2016) 6:20104. doi: 10.1038/srep20104</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20104</ArticleId><ArticleId IdType="pmc">PMC4735587</ArticleId><ArticleId IdType="pubmed">26830021</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer S, Woodward M, Hertel C, Vlaicu P, Haque Y, Karner J, et al. . AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell (2016) 166(3):582&#x2013;95. doi: 10.1016/j.cell.2016.06.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.06.024</ArticleId><ArticleId IdType="pmc">PMC4967814</ArticleId><ArticleId IdType="pubmed">27426947</ArticleId></ArticleIdList></Reference><Reference><Citation>Sng J, Ayoglu B, Chen JW, Schickel JN, Ferre EMN, Glauzy S, et al. . AIRE expression controls the peripheral selection of autoreactive b cells. Sci Immunol (2019) 4(34). doi: 10.1126/sciimmunol.aav6778</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aav6778</ArticleId><ArticleId IdType="pmc">PMC7257641</ArticleId><ArticleId IdType="pubmed">30979797</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez SE, Ferre EM, Scheel DW, Sunshine S, Miao B, Mandel-Brehm C, et al. . Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-seq. Elife (2020) 9. doi: 10.7554/eLife.55053</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.55053</ArticleId><ArticleId IdType="pmc">PMC7228772</ArticleId><ArticleId IdType="pubmed">32410729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Dai Y, Rosen CE, Schmitt MM, Dong MX, Ferre EMN, et al. . High-throughput identification of autoantibodies that target the human exoproteome. Cell Rep Methods (2022) 2(2). doi: 10.1016/j.crmeth.2022.100172</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2022.100172</ArticleId><ArticleId IdType="pmc">PMC8967185</ArticleId><ArticleId IdType="pubmed">35360706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisand K, Peterson P, Laan M. Lymphopenia-induced proliferation in aire-deficient mice helps to explain their autoimmunity and differences from human patients. Front Immunol (2014) 5:51. doi: 10.3389/fimmu.2014.00051</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00051</ArticleId><ArticleId IdType="pmc">PMC3923166</ArticleId><ArticleId IdType="pubmed">24592265</ArticleId></ArticleIdList></Reference><Reference><Citation>Break TJ, Oikonomou V, Dutzan N, Desai JV, Swidergall M, Freiwald T, et al. . Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science (2021) 371(6526). doi: 10.1126/science.aay5731</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay5731</ArticleId><ArticleId IdType="pmc">PMC8326743</ArticleId><ArticleId IdType="pubmed">33446526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol (2020) 16(10):565&#x2013;79. doi: 10.1038/s41584-020-0480-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0480-7</ArticleId><ArticleId IdType="pmc">PMC8456518</ArticleId><ArticleId IdType="pubmed">32884126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, et al. . Analysis of the b cell receptor repertoire in six immune-mediated diseases. Nature (2019) 574(7776):122&#x2013;6. doi: 10.1038/s41586-019-1595-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1595-3</ArticleId><ArticleId IdType="pmc">PMC6795535</ArticleId><ArticleId IdType="pubmed">31554970</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillatreau S, Manfroi B, Dorner T. Toll-like receptor signalling in b cells during systemic lupus erythematosus. Nat Rev Rheumatol (2021) 17(2):98&#x2013;108. doi: 10.1038/s41584-020-00544-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00544-4</ArticleId><ArticleId IdType="pmc">PMC7747191</ArticleId><ArticleId IdType="pubmed">33339987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev (2019) 288(1):136&#x2013;48. doi: 10.1111/imr.12741</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12741</ArticleId><ArticleId IdType="pmc">PMC6422038</ArticleId><ArticleId IdType="pubmed">30874345</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. . European League against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol (2019) 71(9):1400&#x2013;12. doi: 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. . 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol (2017) 69(1):35&#x2013;45. doi: 10.1002/art.39859</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39859</ArticleId><ArticleId IdType="pmc">PMC5650478</ArticleId><ArticleId IdType="pubmed">27785888</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Wang L, Bao D, Wang L, Zhao H, Lian Y, et al. . Novel autoantibodies related to cell death and DNA repair pathways in systemic lupus erythematosus. Genomics Proteomics Bioinf (2019) 17(3):248&#x2013;59. doi: 10.1016/j.gpb.2018.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2018.11.004</ArticleId><ArticleId IdType="pmc">PMC6818352</ArticleId><ArticleId IdType="pubmed">31494269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, et al. . Identification of autoantibody biomarkers for primary sjogren's syndrome using protein microarrays. Proteomics (2011) 11(8):1499&#x2013;507. doi: 10.1002/pmic.201000206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201000206</ArticleId><ArticleId IdType="pmc">PMC3209962</ArticleId><ArticleId IdType="pubmed">21413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in sjogren's syndrome. Rheum Dis Clin North Am (2016) 42(3):419&#x2013;34. doi: 10.1016/j.rdc.2016.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2016.03.002</ArticleId><ArticleId IdType="pmc">PMC4955792</ArticleId><ArticleId IdType="pubmed">27431345</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. . Sjogren's syndrome: a systemic autoimmune disease. Clin Exp Med (2022) 22(1):9&#x2013;25. doi: 10.1007/s10238-021-00728-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00728-6</ArticleId><ArticleId IdType="pmc">PMC8863725</ArticleId><ArticleId IdType="pubmed">34100160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai L, Zhou X, Chen H, Luo Y, Sui W, Zhang J, et al. . Composition and diversity analysis of the b-cell receptor immunoglobulin heavy chain complementarity-determining region 3 repertoire in patients with acute rejection after kidney transplantation using high-throughput sequencing. Exp Ther Med (2019) 17(3):2206&#x2013;20. doi: 10.3892/etm.2019.7183</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.7183</ArticleId><ArticleId IdType="pmc">PMC6395953</ArticleId><ArticleId IdType="pubmed">30867706</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWolf S, Grinshpun B, Savage T, Lau SP, Obradovic A, Shonts B, et al. . Quantifying size and diversity of the human T cell alloresponse. JCI Insight (2018) 3(15). doi: 10.1172/jci.insight.121256</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.121256</ArticleId><ArticleId IdType="pmc">PMC6129121</ArticleId><ArticleId IdType="pubmed">30089728</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson CT, Breden F. The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease. Genes Immun (2012) 13(5):363&#x2013;73. doi: 10.1038/gene.2012.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2012.12</ArticleId><ArticleId IdType="pubmed">22551722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappione A, 3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, et al. . Germinal center exclusion of autoreactive b cells is defective in human systemic lupus erythematosus. J Clin Invest (2005) 115(11):3205&#x2013;16. doi: 10.1172/JCI24179</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI24179</ArticleId><ArticleId IdType="pmc">PMC1242189</ArticleId><ArticleId IdType="pubmed">16211091</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimge NO, Pramanik S, Hu G, Lin Y, Gao R, Shen L, et al. . Determination of gene organization in the human IGHV region on single chromosomes. Genes Immun (2005) 6(3):186&#x2013;93. doi: 10.1038/sj.gene.6364176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364176</ArticleId><ArticleId IdType="pubmed">15744329</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne-Steele M, et al. . Belimumab promotes negative selection of activated autoreactive b cells in systemic lupus erythematosus patients. JCI Insight (2018) 3(17). doi: 10.1172/jci.insight.122525</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.122525</ArticleId><ArticleId IdType="pmc">PMC6171800</ArticleId><ArticleId IdType="pubmed">30185675</ArticleId></ArticleIdList></Reference><Reference><Citation>Meffre E, Milili M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, Schiff C. Immunoglobulin heavy chain expression shapes the b cell receptor repertoire in human b cell development. J Clin Invest (2001) 108(6):879&#x2013;86. doi: 10.1172/JCI13051</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI13051</ArticleId><ArticleId IdType="pmc">PMC200933</ArticleId><ArticleId IdType="pubmed">11560957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowan GJM, Miles K, Capitani L, Giguere SSB, Johnsson H, Goodyear C, et al. . In human autoimmunity, a substantial component of the b cell repertoire consists of polyclonal, barely mutated IgG(+ve) b cells. Front Immunol (2020) 11:395. doi: 10.3389/fimmu.2020.00395</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00395</ArticleId><ArticleId IdType="pmc">PMC7099054</ArticleId><ArticleId IdType="pubmed">32265907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakakibara S, Arimori T, Yamashita K, Jinzai H, Motooka D, Nakamura S, et al. . Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Sci Rep (2017) 7(1):16428. doi: 10.1038/s41598-017-16681-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16681-y</ArticleId><ArticleId IdType="pmc">PMC5703881</ArticleId><ArticleId IdType="pubmed">29180749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindmark E, Chen Y, Georgoudaki AM, Dudziak D, Lindh E, Adams WC, et al. . AIRE expressing marginal zone dendritic cells balances adaptive immunity and T-follicular helper cell recruitment. J Autoimmun (2013) 42:62&#x2013;70. doi: 10.1016/j.jaut.2012.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2012.11.004</ArticleId><ArticleId IdType="pubmed">23265639</ArticleId></ArticleIdList></Reference><Reference><Citation>Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol (2022) 40:413&#x2013;42. doi: 10.1146/annurev-immunol-120419-022408</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-120419-022408</ArticleId><ArticleId IdType="pubmed">35113731</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalina MD, Bachali P, Yeo AE, Geraci NS, Petri MA, Grammer AC, et al. . Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight (2020) 5(15). doi: 10.1172/jci.insight.140380</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140380</ArticleId><ArticleId IdType="pmc">PMC7455079</ArticleId><ArticleId IdType="pubmed">32759501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheumatol (2005) 52(5):1491&#x2013;503. doi: 10.1002/art.21031</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun (2007) 8(6):492&#x2013;502. doi: 10.1038/sj.gene.6364408</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364408</ArticleId><ArticleId IdType="pmc">PMC2702174</ArticleId><ArticleId IdType="pubmed">17581626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Herrmann M, Munoz LE. Clearance deficiency and cell death pathways: A model for the pathogenesis of SLE. Front Immunol (2016) 7:35. doi: 10.3389/fimmu.2016.00035</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00035</ArticleId><ArticleId IdType="pmc">PMC4745266</ArticleId><ArticleId IdType="pubmed">26904025</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Zhuang H, Shumyak S, Yang L, Reeves WH. Mechanisms of autoantibody production in systemic lupus erythematosus. Front Immunol (2015) 6:228. doi: 10.3389/fimmu.2015.00228</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00228</ArticleId><ArticleId IdType="pmc">PMC4429614</ArticleId><ArticleId IdType="pubmed">26029213</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med (2020) 382(3):211&#x2013;21. doi: 10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferre EMN, Break TJ, Burbelo PD, Allgauer M, Kleiner DE, Jin D, et al. . Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci Transl Med (2019) 11(495). doi: 10.1126/scitranslmed.aav5597</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav5597</ArticleId><ArticleId IdType="pmc">PMC6647037</ArticleId><ArticleId IdType="pubmed">31167928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>